# Nykode Therapeutics

Source: https://onco.cc/companies/nykode-therapeutics/  
OnCo record `nykode-therapeutics` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Nykode makes cancer vaccines that teach the immune system to attack tumours. One is built from each patient's own tumour mutations; another targets cancers caused by the HPV16 virus, such as cervical cancer.

## Summary

Nykode Therapeutics (Euronext Oslo: NYKD) develops immunotherapies on its Vaccibody platform, a DNA-encoded molecule that delivers antigens to antigen-presenting cells to induce strong and durable T cell responses. VB10.16 (abi-suva) is an off-the-shelf vaccine against HPV16 E6 and E7. In the phase 2 VB-C-02 trial in advanced cervical cancer with atezolizumab, median progression-free survival was 6.3 months and median overall survival was not reached beyond 25 months in PD-L1 positive patients (April 2023). A collaboration with MSD tests VB10.16 with pembrolizumab in HPV16-positive head and neck cancer. VB10.NEO is a fully individualised neoantigen vaccine with optimised manufacturing reported in 2026. In August 2026 Nykode raised about NOK 286 million in a private placement to fund VB10.NEO partnering, the move of abi-suva from phase 2 to phase 3 and a tolerance platform, with shareholders Rasmussengruppen and Andenæsgruppen participating.

## Fields

- Kind: Company
- Last checked: 2026-09-10
- HQ: Oslo
- Type: biotech
- Website: https://www.nykode.com
- Ticker: NYKD.OL

## Notes

- Founding year not sourced.

## Sources

- Official website: https://www.nykode.com
- Private placement completed (August 2026): https://nykode.com/wp-content/uploads/2026/09/260827-Private-Placement-Completed.pdf
- Phase 2 VB10.16 final results in cervical cancer: https://www.globenewswire.com/news-release/2023/04/18/2649342/0/en/nykode-therapeutics-announces-positive-final-results-from-its-phase-2-trial-of-vb10-16-in-combination-with-pd-l1-inhibitor-atezolizumab-in-advanced-cervical-cancer.html
- MSD clinical collaboration in HPV16-positive head and neck cancer: https://www.globenewswire.com/news-release/2022/12/06/2568545/0/en/nykode-therapeutics-announces-clinical-collaboration-with-msd-to-evaluate-vb10-16-in-combination-with-keytruda-pembrolizumab-in-patients-with-hpv16-positive-head-and-neck-cancer.html

## Connected records

- cancers: [Cervical cancer](https://onco.cc/cancers/cervical/), [Head and neck squamous cell carcinoma](https://onco.cc/cancers/head-and-neck/)
- fronts: [Immunotherapy](https://onco.cc/fronts/immunotherapy/)
- technologies: [Off-the-shelf cancer vaccines](https://onco.cc/technologies/shared-antigen-vaccine/), [Personalised neoantigen (mRNA) vaccines](https://onco.cc/technologies/neoantigen-mrna-vaccine/)

---
JSON: https://onco.cc/api/v1/entities/nykode-therapeutics.json